New insights into the role of PPARs

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 85, Issue 5, 2011, Pages 235-243

  Montagner, Alexandra ^a   Rando, Gianpaolo ^a   Degueurce, Gwendoline ^a   Leuenberger, Nicolas ^a   Michalik, Liliane ^a   Wahli, Walter ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;

ARTICLE; CELL MIGRATION; CELL SURVIVAL; CIRCADIAN RHYTHM; DOWN REGULATION; FIBROBLAST; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; INTRACELLULAR SIGNALING; KERATINOCYTE; LIPOLYSIS; LIVER INJURY; LIVER METABOLISM; LIVER PROTECTION; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; PSORIASIS; SEX DIFFERENCE; SKIN INJURY; SUMOYLATION; WOUND HEALING;

ANIMALS; CHOLESTASIS, INTRAHEPATIC; ENERGY METABOLISM; ESTROGENS; FATTY ACIDS; FEMALE; HUMANS; INTERLEUKIN-1; KERATINOCYTES; LIVER; MALE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION; SKIN; WOUND HEALING;

MAMMALIA;

EID: 80053583204     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2011.04.016     Document Type: Article

References (69)

1. Desvergne B., Michalik L., Wahli W. Transcriptional regulation of metabolism. Physiol. Rev. 2006, 86:465-514.
2. Michalik L., Auwerx J., Berger J.P., et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006, 58:726-741.
3. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992, 68:879-887.
4. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347:645-650.
5. Laudet V., Auwerx J., Gustafsson J.A., Wahli W. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999, 97:161-163.
6. Feige J.N., Gelman L., Michalik L., Desvergne B., Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res. 2006, 45:120-159.
7. Imai T., Takakuwa R., Marchand S., et al. Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc. Natl. Acad. Sci. USA 2004, 101:4543-4547.
8. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994, 8:1224-1234.
9. Fuchs E., Raghavan S. Getting under the skin of epidermal morphogenesis. Nat. Rev. Genet. 2002, 3:199-209.
10. Karnik P., Tekeste Z., McCormick T.S., Gilliam A.C., Price V.H., Cooper K.D., Mirmirani P. Hair follicle stem cell-specific PPARγ deletion causes scarring alopecia. J. Invest. Dermatol. 2009, 129:1243-1257.
11. Schmuth M., Jiang Y.J., Dubrac S., Elias P.M., Feingold K.R. Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J. Lipid Res. 2008, 49:499-509.
12. Michalik L., Wahli W. Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim. Biophys. Acta 2007, 1771:991-998.
13. Michalik L., Desvergne B., Tan N.S., et al. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J. Cell Biol. 2001, 154:799-814.
14. Tan N.S., Michalik L., Noy N., et al. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev. 2001, 15:3263-3277.
15. Tan N.S., Michalik L., Di-Poi N., et al. Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/delta expression. EMBO J. 2004, 23:4211-4221.
16. Di-Poi N., Ng C.Y., Tan N.S., et al. Epithelium-mesenchyme interactions control the activity of peroxisome proliferator-activated receptor beta/delta during hair follicle development. Mol. Cell Biol. 2005, 25:1696-1712.
17. Tan N.S., Michalik L., Desvergne B., Wahli W. Genetic- or transforming growth factor-beta 1-induced changes in epidermal peroxisome proliferator-activated receptor beta/delta expression dictate wound repair kinetics. J. Biol. Chem. 2005, 280:18163-18170.
18. Chong H.C., Tan M.J., Philippe V., et al. Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta/delta is essential for skin homeostasis and wound healing. J. Cell Biol. 2009, 184:817-831.
19. Frame M.C. Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta 2002, 1602:114-130.
20. Chu C.Y., Cha S.T., Lin W.C., et al. Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1/2-NF-kappaB/interleukin-6 pathway. Carcinogenesis 2009, 30:205-213.
21. C. Hafner, M. Landthaler and T. Vogt, Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations, Exp. Dermatol. (2010).
22. Rivier M., Safonova I., Lebrun P., Griffiths C.E., Ailhaud G., Michel S. Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J. Invest. Dermatol. 1998, 111:1116-1121.
23. Westergaard M., Henningsen J., Johansen C., et al. Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J. Invest. Dermatol. 2003, 121:1104-1117.
24. Romanowska M., Reilly L., Palmer C.N., Gustafsson M.C., Foerster J. Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo. PLoS One 2010, 5:e9701.
25. Ellis C.N., Varani J., Fisher G.J., Zeigler M.F., Pershadsingh H.A., Benson S.C., Chi Y., Kurtz T.W. Troglitazone improves psoriasis and normalizes models of proliferative skin disease. Arch. Dermatol. 2000, 136:609-616.
26. Nijsten T., Geluyckens E., Colpaert C., Lambert J. Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors. J. Cutaneous Pathol. 2005, 32:340-347.
27. Sertznig P., Seifert M., Tilgen W., Reichrath J. Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases. Am. J. Clin. Dermatol. 2008, 9:15-31.
28. Wagner K.D., Wagner N. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol. Ther. 2010, 125:423-435.
29. Michalik L., Wahli W. PPARs mediate lipid signaling in inflammation and cancer. PPAR Res. 2008, 2008:134059.
30. J.M. Peters and F.J. Gonzalez, Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer, Biochim. Biophys. Acta 1796 (2009) 230-241.
31. Kersten S., Mandard S., Tan N.S., et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 2000, 275:28488-28493.
32. Pan D., Fujimoto M., Lopes A., Wang Y.X. Twist-1 is a PPARdelta-inducible, negative-feedback regulator of PGC-1alpha in brown fat metabolism. Cell 2009, 137:73-86.
33. Kim H.J., Ham S.A., Kim S.U., et al. Transforming growth factor-beta1 is a molecular target for the peroxisome proliferator-activated receptor delta. Circ. Res. 2008, 102:193-200.
34. Schug T.T., Berry D.C., Shaw N.S., Travis S.N., Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 2007, 129:723-733.
35. Kannan-Thulasiraman P., Seachrist D.D., Mahabeleshwar G.H., Jain M.K., Noy N. Fatty acid-binding protein 5 and PPARbeta/delta are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. J. Biol. Chem. 2010, 285:19106-19115.
36. Peters J.M., Rusyn I., Rose M.L., Gonzalez F.J., Thurman R.G. Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis 2000, 21:823-826.
37. Hellemans K., Michalik L., Dittie A., et al. Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 2003, 124:184-201.
38. Patsouris D., Reddy J.K., Muller M., Kersten S. Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 2006, 147:1508-1516.
39. Dreyer C., Keller H., Mahfoudi A., Laudet V., Krey G., Wahli W. Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol. Cell 1993, 77:67-76.
40. Kersten S., Seydoux J., Peters J.M., Gonzalez F.J., Desvergne B., Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 1999, 103:1489-1498.
41. Kersten S., Mandard S., Escher P., et al. The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism. FASEB J 2001, 15:1971-1978.
42. Leuenberger N., Wahli W. PPARalpha, a key regulator of hepatic energy homeostasis in health and disease. Signaling Pathways in Liver Diseases 2010, 305-315. Springer, Berlin Heidelberg. J.-F. Dufour, P.-A. Clavien (Eds.).
43. T. Lemberger, R. Saladin, M. Vazquez, et al., Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm, J. Biol. Chem. 271 (1996) 1764-1769.
44. Yang X., Downes M., Yu R.T., et al. Nuclear receptor expression links the circadian clock to metabolism. Cell 2006, 126:801-810.
45. Chen P., Kakan X., Zhang J. Altered circadian rhythm of the clock genes in fibrotic livers induced by carbon tetrachloride. FEBS Lett. 2010, 584:1597-1601.
46. Gachon F., Olela F.F., Schaad O., Descombes P., Schibler U. The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 2006, 4:25-36.
47. Rotman N., Wahli W. Fatty acid synthesis and PPARalpha hand in hand. Chem. Biol. 2009, 16:801-802.
48. Chakravarthy M.V., Lodhi I.J., Yin L., et al. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 2009, 138:476-488.
49. Gachon F., Leuenberger N., Claudel T., Gos P., Jouffe C., FleuryOlela F., deMolleratduJeu X., Wahli W., Schibler U. Proline- and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor α (PPARα) activity. Proc. Natl. Acad. Sci. USA 2011, 108:4794-4799.
50. Schmutz I., Ripperger J.A., Baeriswyl-Aebischer S., Albrecht U. The mammalian clock component PERIOD2 coordinates circadian output by interaction with nuclear receptors. Genes Dev. 2010, 24:345-357.
51. Canaple L., Rambaud J., Dkhissi-Benyahya O., et al. Reciprocal regulation of brain and muscle Arnt-like protein 1 and peroxisome proliferator-activated receptor alpha defines a novel positive feedback loop in the rodent liver circadian clock. Mol. Endocrinol. 2006, 20:1715-1727.
52. Clodfelter K.H., Holloway M.G., Hodor P., Park S.H., Ray W.J., Waxman D.J. Sex-dependent liver gene expression is extensive and largely dependent upon signal transducer and activator of transcription 5b (STAT5b): STAT5b-dependent activation of male genes and repression of female genes revealed by microarray analysis. Mol. Endocrinol. 2006, 20:1333-1351.
53. Holloway M.G., Cui Y., Laz E.V., Hosui A., Hennighausen L., Waxman D.J. Loss of sexually dimorphic liver gene expression upon hepatocyte-specific deletion of Stat5a-Stat5b locus. Endocrinology 2007, 148:1977-1986.
54. Yokomori N., Kobayashi R., Moore R., Sueyoshi T., Negishi M. A DNA methylation site in the male-specific P450 (Cyp 2d-9) promoter and binding of the heteromeric transcription factor GABP. Mol. Cell Biol. 1995, 15:5355-5362.
55. Costet P., Legendre C., More J., Edgar A., Galtier P., Pineau T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J. Biol. Chem. 1998, 273:29577-29585.
56. Djouadi F., Weinheimer C.J., Saffitz J.E., et al. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice. J. Clin. Invest. 1998, 102:1083-1091.
57. Jalouli M., Carlsson L., Ameen C., et al. Sex difference in hepatic peroxisome proliferator-activated receptor alpha expression: influence of pituitary and gonadal hormones. Endocrinology 2003, 144:101-109.
58. Gray R.H., de la Iglesia F.A. Quantitative microscopy comparison of peroxisome proliferation by the lipid-regulating agent gemfibrozil in several species. Hepatology 1984, 4:520-530.
59. Ciana P., Biserni A., Tatangelo L., et al. A novel peroxisome proliferator-activated receptor responsive element-luciferase reporter mouse reveals gender specificity of peroxisome proliferator-activated receptor activity in liver. Mol. Endocrinol. 2007, 21:388-400.
60. Leuenberger N., Pradervand S., Wahli W. Sumoylated PPARalpha mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice. J. Clin. Invest. 2009, 119:3138-3148.
61. Pourcet B., Pineda-Torra I., Derudas B., Staels B., Glineur C. SUMOylation of human peroxisome proliferator-activated receptor alpha inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR. J. Biol. Chem. 2010, 285:5983-5992.
62. Tang W., Eggertsen G., Chiang J.Y., Norlin M. Estrogen-mediated regulation of CYP7B1: a possible role for controlling DHEA levels in human tissues. J. Steroid Biochem. Mol. Biol. 2006, 100:42-51.
63. Pettersson H., Holmberg L., Axelson M., Norlin M. CYP7B1-mediated metabolism of dehydroepiandrosterone and 5alpha-androstane-3beta,17beta-diol-potential role(s) for estrogen signaling. FEBS J. 2008, 275:1778-1789.
64. Martin C., Bean R., Rose K., Habib F., Seckl J. cyp7b1 catalyses the 7alpha-hydroxylation of dehydroepiandrosterone and 25-hydroxycholesterol in rat prostate. Biochem. J. 2001, 355:509-515.
65. Umetani M., Domoto H., Gormley A.K., et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 2007, 13:1185-1192.
66. Yamamoto Y., Moore R., Hess H.A., et al. Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. J. Biol. Chem. 2006, 281:16625-16631.
67. Pusl T., Beuers U. Intrahepatic cholestasis of pregnancy. Orphanet J. Rare Dis. 2007, 2:26.
68. Keller H., Givel F., Perroud M., Wahli W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol. Endocrinol. 1995, 9:794-804.
69. Hewitt K.N., Pratis K., Jones M.E., Simpson E.R. Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. Endocrinology 2004, 145:1842-1848.